“As I said before, we should be exploring strate
Post# of 148162
Great post TG. As I’ve said before, IMO, CYDY has been approached in the past for partnerships for HIV and COVID. I believe NP’s pride prevented those partnerships from occurring. The Vyera deal is an anomaly and not the standard, so yes, a partnership with BP would be in the 20% range. CYDY needs the revenues and the name recognition. The same goes for longhaulers. Some investors disagree, but 100% of zero is zero and we know BP has a track record of getting drugs to the market (R&D, lobbyist, etc.).